01 · ABSTRACT
Background: Cancer remains one of the most prevalent and life-threatening diseases of the modern era, driven by complex genetic and epigenetic factors. The pathogenesis of chronic malignancy is primarily dominated by three critical mechanisms: systemic inflammation, oxidative stress, and endothelial dysfunction. Maintaining the integrity of these cellular processes is vital for health preservation. In this context, micronutrients such as vitamins, trace elements, and minerals play a fundamental role. However, cancer patients often suffer from severe malnutrition, cachexia, and significant weight loss due to the disease progression or the side effects of chemotherapy and radiotherapy, such as nausea and loss of appetite. This nutritional decline severely impairs the quality of life and is a major contributor to early mortality.
Aim: This study aimed to evaluate the efficacy of a targeted nutritional intervention using five specific functional food supplements to reverse malnutrition-related appetite loss and weight reduction. The investigation focused on whether achieving cellular saturation with key micronutrients, macronutrients, and pro-prebiotics could modulate inflammatory and oxidative pathways, thereby improving nutritional status and survival outcomes in Stage IV metastatic cancer patients.
Methods: The study cohort consisted of 98 adult patients (51 men, 47 women; median age 61) with Stage IV metastatic stomach (n=18), breast (n=18), colon (n=18), lung (n=24), and pancreatic cancer (n=20) who had completed conventional treatments. Initial body weights were critically low, ranging between 31-44 kg. The 48-month intervention involved a daily oral regimen of: Morinda citrifolia (anti-atherosclerotic liquid- AAL), Omega-3(anti-inflammatory capsules- AIC), Alaskan blueberry and 21 red-purple fruit-vegetable extract (antioxidant liquid- AOL), collagen (type1-3 collagen liquid-CL) and pro-prebiotic (Pro-prebiotic capsules- PPC). In the first 12 months, only 3 food items were given, but in the following 3 years, patients were given two more food items containing collagen and pro-prebiotics.
Results: At the end of the first year, 74 of the 98 patients survived. By the fourth year, 42 patients remained alive, with their body weights significantly increasing to a range of 55-81 kg. The synergistic effect of AOL, AIC, AAL, CL, and PPC ensured the restoration of essential nutrient levels at the cellular level. This intervention effectively prevented malnutrition, leading to a substantial increase in appetite and sustainable weight gain.
Conclusion: Targeted micronutrition, incorporating vitamins, minerals, collagen, and pro-prebiotics, addresses the root causes of malnutrition in advanced cancer. By correcting cellular deficiencies, this approach significantly improves appetite, promotes weight gain, and enhances both the quality of life and long-term survival in metastatic patients.
↓ Read PDF02 · OJS METADATA
Metastatic cancerFunctional food supplementsMalnutritionMicronutritionOxidative stressSystemic inflammationEndothelial dysfunctionCachexia
03 · PUBLICATION RECORD
JournalMedical Research Archives
IssueVol 14 No 4 (2026): Vol.14 Issue 4 April 2026
SectionResearch Articles
Published30 April 2026
DOI10.18103/mra.v14i4.7427
ISSN2375-1924
04 · RIGHTS & REUSE
This article is published under a Creative Commons Attribution License (CC BY 3.0) and may be shared or distributed by anyone as long as attribution is given to the journal.
Submit your own article
Register as an author to reserve your spot in the next issue of the Medical Research Archives.
Start your submission ↗Recommended reading
Related articles
The microRNA miR-516a-3p regulates the Wnt pathway by targeting extracellular sulfatase 1 in human scirrhous gastric cancers: Anti-metastatic therapy via miRNA-based medicine
Yoshifumi Takei et al.
What Health Care Providers Know and How They Communicate Breast Cancer Risk to Patients
Marlyn Allicock et al.
Retroactive assessment for DNA mismatch repair deficiency in women with a history of endometrial cancer
Y. Stefanie Chen et al.